Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK7 | Q13164 | 13/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.53 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802604 | 0.79 | MAP2K1 (0.45) | POLBALDH1A1 | |
| SCHEMBL5311108 | 0.78 | ALDH1A1 (0.68) | POLBMAPK7ALDH1A1PKML3MBTL1 | |
| SCHEMBL5543840 | 0.76 | LMNA (0.46) | POLBALDH1A1PKML3MBTL1TDP1 | |
| SCHEMBL5537048 | 0.75 | LMNA (0.44) | POLBALDH1A1PKML3MBTL1TDP1 | |
| SCHEMBL5535242 | 0.74 | SMN1; SMN2 (0.46) | POLBALDH1A1L3MBTL1 | |
| SCHEMBL5537750 | 0.74 | SMN1; SMN2 (0.46) | POLBALDH1A1PKML3MBTL1TDP1 | |
| SCHEMBL300049 | 0.74 | POLB (0.68) | POLBMAPK7MAPK14YTHDC1ALDH1A1 | |
| SCHEMBL4960341 | 0.73 | USP2 (0.52) | ALDH1A1PKMTDP1 | |
| SCHEMBL17607070 | 0.71 | MAPK7 (0.63) | POLBMAPK7MAPK14ALDH1A1PKM | |
| SCHEMBL20265900 | 0.71 | MAPK7 (0.69) | MAPK7MAPK14YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | MAP3K19, MAP3K1, MAP3K7 | POLB 1688/4885MAPK7 40/4885MAPK14 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.